Third, preliminary evidence suggests that the MAFLD definition might better capture patients who might benefit from an evaluation of genetic risks for fatty liver, as PNPLA3 rs738409 seems to be associated with MAFLD [48], but also with the development of kidney abnormalities [23,49]. This evidence concerns the gene PNPLA3 and Hepatic steatosis.